STAT

NOVEMBER 18, 2023

The revolution started in silence. Jennifer Doudna and Emmanuelle Charpentier, now Nobelists , published their first paper announcing a new enzyme for editing DNA in Science in June 2012. It was called CRISPR-Cas9. It wasn’t until January 2013 that the first paper showing the enzyme would work in cells, from Feng Zhang, was published, also in Science.

145

145

Pharmaceutical Technology

NOVEMBER 18, 2023

MRNA-1083 is under clinical development by Moderna and currently in Phase III for Influenzavirus B Infections.

52

52

STAT

NOVEMBER 18, 2023

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor here , or find the submission form at the end of any First Opinion essay. “ The end of affirmative action means it’s time to revise pre-med requirements ,” by David Velasquez The ability to do well in both general and organic chemistry as well as physics that requires calculus are cours

102

102

Pharmaceutical Technology

NOVEMBER 18, 2023

LuAG-09222 is under clinical development by H. Lundbeck and currently in Phase II for Migraine.

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

The Guardian - Pharmaceutical Industry

NOVEMBER 18, 2023

Drug firm Novo Nordisk proposed singling out those most likely to return to work with its weight-loss injection Obesity jab maker Novo Nordisk suggested to senior government officials that they could “profile” benefit claimants so that those most likely to return to work could be targeted with its weight-loss injections. Internal documents obtained by the Observer reveal that Pinder Sahota, corporate vice-president of Novo Nordisk UK, told the then health secretary Steve Barclay, England’s chief

Documentation 107

Documentation 107

Pharmaceutical Technology

NOVEMBER 18, 2023

BB-1701 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

Fostroxacitabine Bralpamide Hydrochloride is a small molecule commercialized by Medivir, with a leading Phase II program in Hepatocellular Carcinoma.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

TSC-200-A0201 is a gene-modified cell therapy commercialized by TScan Therapeutics, with a leading Phase I program in Metastatic Ovarian Cancer.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

TSC-200-A0201 is a gene-modified cell therapy commercialized by TScan Therapeutics, with a leading Phase I program in Metastatic Ovarian Cancer.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

RPA-501 is a gene therapy commercialized by Rocket Pharmaceuticals, with a leading Phase II program in Glycogen Storage Disorders (GSD).

40

40

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmaceutical Technology

NOVEMBER 18, 2023

Rilzabrutinib is under clinical development by Principia Biopharma and currently in Phase II for Acquired (Autoimmune) Hemolytic Anemia.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

Mirikizumab is under clinical development by Eli Lilly and Co and currently in Phase III for Crohn's Disease (Regional Enteritis).

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

Aflibercept Biosimilar. is a fusion protein commercialized by Celltrion, with a leading Phase III program in Diabetic Macular Edema.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

Aflibercept Biosimilar. is a fusion protein commercialized by Celltrion, with a leading Phase III program in Diabetic Macular Edema.

40

40

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmaceutical Technology

NOVEMBER 18, 2023

Tusamitamab ravtansine is under clinical development by Sanofi and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma).

52

52

Pharmaceutical Technology

NOVEMBER 18, 2023

APHD-012 is under clinical development by Aphaia Pharma and currently in Phase II for Pre-Diabetes/Impaired Glucose Tolerance.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

MRNA-1083 is under clinical development by Moderna and currently in Phase III for Influenza A Virus, H1N1 Subtype Infections.

52

52

Pharmaceutical Technology

NOVEMBER 18, 2023

MRNA-1083 is under clinical development by Moderna and currently in Phase III for Influenza A Virus, H3N2 Subtype Infections.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

Basmisanil is a small molecule commercialized by F. Hoffmann-La Roche, with a leading Phase II program in Dup15q Syndrome.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

Basmisanil is a small molecule commercialized by F. Hoffmann-La Roche, with a leading Phase II program in Dup15q Syndrome.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

KT-413 is a small molecule commercialized by Kymera Therapeutics, with a leading Phase I program in Primary CNS Lymphoma.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

PXVX-0317 is a subunit vaccine commercialized by Bavarian Nordic, with a leading Phase III program in Chikungunya Fever.

Vaccines 40

Vaccines 40

Pharmaceutical Technology

NOVEMBER 18, 2023

BB-1701 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase II for Solid Tumor.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

Icovamenib is a small molecule commercialized by Biomea Fusion, with a leading Phase II program in Type 2 Diabetes.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

Icovamenib is a small molecule commercialized by Biomea Fusion, with a leading Phase II program in Type 2 Diabetes.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

MRNA-3705 is a gene therapy commercialized by Moderna, with a leading Phase II program in Methylmalonic Acidemia.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

MRNA-3705 is a gene therapy commercialized by Moderna, with a leading Phase II program in Methylmalonic Acidemia.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

Amphotericin B is under clinical development by Cystetic Medicines and currently in Phase I for Cystic Fibrosis.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

Tusamitamab ravtansine is under clinical development by Sanofi and currently in Phase II for Endometrial Cancer.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

PF-07257876 is under clinical development by Pfizer and currently in Phase I for Non-Small Cell Lung Carcinoma.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

Tusamitamab ravtansine is under clinical development by Sanofi and currently in Phase II for Colorectal Cancer.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

Tusamitamab ravtansine is under clinical development by Sanofi and currently in Phase II for Pancreatic Cancer.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

Tusamitamab ravtansine is under clinical development by Sanofi and currently in Phase II for Cervical Cancer.

40

40

Pharmaceutical Technology

NOVEMBER 18, 2023

MRNA-4157 is a mrna vaccine commercialized by Merck, with a leading Phase II program in Metastatic Melanoma.

Vaccines 40

Vaccines 40